share_log

Xcelerate, Inc. Announces PTO and PCT Filings For Surgical Devices

Xcelerate, Inc. Announces PTO and PCT Filings For Surgical Devices

Xcelerate, Inc. 宣佈手術器械的 PTO 和 PCT 申請
Accesswire ·  2023/04/20 08:30

MAULDIN, SC / ACCESSWIRE / April 20, 2023 / Xcelerate, Inc. (OTCQB:XCRT) announced today it filed two utility patent applications under application numbers 18/187,352 and 18/189,441. Additionally, corresponding PCT applications were filed under PCT/US2023/015755 and PCT/US2023/016194. Both applications are claiming priority to Xcelerate's patent application "Surgical Tools with Targeting Guidance", filed under application number 63/323,112 on March 24th, 2022.

南卡羅來納州莫爾丁/Accesswire/2023 年 4 月 20 日/ Xcelerate, Inc. (OTCQB: XCRT) 今天宣佈,它提交了兩項實用專利申請,申請編號爲18/187,352和189,441。此外,相應的PCT申請是根據PCT/US2023/015755和PCT/US2023/016194提交的。這兩項申請都聲稱擁有Xcelerate的專利申請 “帶靶向指導的手術工具” 的優先權,該申請於2022年3月24日以63/323,112號申請提交。

These applications represent the continuation of Xcelerate's stated mission of "utilizing non-medical engineering advancements and applying them to clinical care". The co-inventors of these patent application are Xcelerate Advisory Board members Dr. Anja Glisovic and Dr. Dilan Ellegala.

這些應用代表着Xcelerate既定使命的延續,即 “利用非醫學工程進步並將其應用於臨牀護理”。這些專利申請的共同發明人是Xcelerate顧問委員會成員安雅·格利索維奇博士和迪蘭·埃勒加拉博士。

"These filings represent just one facet of our approach of parallel development, testing and IP-protection of our surgical device lines. We are also proud to unveil first images from our In-Tool-Optics prototypes, which are covered by the filed patents." said Michael O'Shea Xcelerate's CEO.

“這些文件只是我們對手術器械繫列進行平行開發、測試和知識產權保護的方法的一個方面。我們還很自豪地公佈了我們的In-Tool-Optics原型的第一張圖片,這些圖像受已申請的專利保護。” Xcelerate首席執行官邁克爾·奧謝伊說。

Dr. Anja Glisovic commented, "A first-person view is most intuitive to us, and we naturally gravitate to it, for example, in virtual reality or computer games. With the advent of minimally invasive surgery, it was partly lost in favor of the endoscope's "third-person view" in medicine. With the In-Tool-Optics series of surgical instruments and devices we bring a new "first-person view" to the surgical theatre. By integrating cameras directly into surgical tools, we allow the surgeon to follow and perform the procedure from the tool's perspective. This new viewpoint has the potential to significantly boost precision and speed of surgical procedures and to reduce the space necessary for several procedures. To further improve this, projection of targeting markers as well as illumination are integrated.

安雅·格利索維奇博士評論說:“第一人稱視角對我們來說是最直觀的,例如,在虛擬現實或電腦遊戲中,我們自然會被它吸引。隨着微創手術的出現,微創手術在一定程度上被消失了,取而代之的是內窺鏡在醫學上的 “第三人稱視角”。藉助 In-Tool-Optics 系列手術器械和設備,我們爲手術室帶來了新的 “第一人稱視角”。通過將攝像頭直接集成到手術工具中,我們允許外科醫生從工具的角度跟蹤和執行手術。這種新視角有可能顯著提高外科手術的精度和速度,並減少多項手術所需的空間。爲了進一步改善這一點,集成了目標標記的投影和照明。

We are currently working on three different In-Tool-Optic (ITO) product lines, ITO-Responder, ITO-Clinic, and ITO-Infirmary. The names are telling. The ITO-Responder line is geared towards Emergency Responders, e.g. civilian and military paramedics. Their ITO products will be disposable and come with a rugged, reusable display for field use and a lot of inbuilt auto-adjustment features to optimize contrast and illumination. They will also conform with NATO standardizations as well as with US regulations. The images below are from one of our ITO-Responder prototypes. ITO-Clinic has a different focus. It is designed for use in hospitals and operating theatres. Products from this line will allow much more features to be adjusted manually by the surgeon. For example, there will be access to the Color Rendering Index (CRI), which is especially crucial in the red color palette to identify and distinguish blood vessels as well as other methods of graphical postprocessing and measurements. Finally, there will be the ITO-Infirmary line. No one would want to throw away fully functional surgical tools just because there is a newer tool available but at the same time, the newest tools provide desirable benefits for patients and surgeons. Xcelerate is aware of this and address this with the ITO-Infirmary product line, which will allow to retrofit existing surgical tools with the mentioned functionalities. Thereby, we hope to cover and address the market and customer needs in the best way possible.

我們目前正在開發三種不同的 In-Tool-Optic (ITO) 產品線, 伊藤-回應者伊藤診所,以及 伊藤醫務室。名字很有說服力。該 ITO-Responder line 適用於應急人員,例如民用和軍事護理人員。他們的 ITO 產品將是一次性的,配備堅固耐用、可重複使用的顯示屏,供現場使用,還有許多內置的自動調整功能,可優化對比度和照明。它們還將符合北約的標準化以及美國的法規。以下圖片來自我們的其中一張 ITO-Responder 原型。 伊藤診所 有不同的重點。它專爲醫院和手術室使用而設計。該系列的產品將允許外科醫生手動調整更多功能。例如,可以訪問顏色渲染指數(CRI),這在紅色調色板中對於識別和區分血管以及其他圖形後處理和測量方法尤其重要。最後,將有 伊藤醫務室 線。沒有人願意僅僅因爲有更新的工具就丟棄功能齊全的手術工具,但與此同時,最新的工具爲患者和外科醫生提供了理想的好處。Xcelerate 意識到了這一點,並通過以下方法解決了這個問題 伊藤醫務室 產品線,這將允許使用上述功能改造現有的手術工具。因此,我們希望以最佳方式涵蓋和滿足市場和客戶需求。

Disposable Clamp with InTool device prototype and Figure 2: View from the tool's perspective, provided by In-Tool- Dime for scale. Optics

帶有 InTool 設備原型和圖 2:從工具的角度看的一次性夾子,由 In-Tool-Dime 提供,用於縮放。光學

ABOUT XCELERATE INC.

關於 XCELERATE INC.

In May 2020, Xcelerate commenced implementation of a new business plan that encompasses two separate but related businesses within the medical industry, including (i) owning and licensing the rights to various forms of medical equipment and portfolio of patents, patents pending and technology licenses and (ii) development of virtual health technology to assist patients in developing countries obtain medical care by extending the reach of physicians through the use of that technology. For more information visit or contact us at 854-900-2020 or email info@xcelerate.global.

2020年5月,Xcelerate開始實施一項新的業務計劃,該計劃涵蓋醫療行業內兩項獨立但相關的業務,包括(i)擁有和許可各種形式的醫療設備以及專利、待批專利和技術許可組合的權利;(ii)開發虛擬健康技術,通過使用該技術擴大醫生的覆蓋範圍,幫助發展中國家的患者獲得醫療服務。欲瞭解更多信息,請訪問或致電 854-900-2020 聯繫我們或發送電子郵件至 info@xcelerate.global。

SAFE HARBOR

安全港

This press release may contain forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), including all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, its directors or its officers with respect to, among other things: (i) the Company's financing plans; (ii) trends affecting the Company's financial condition or results of operations; (iii) the Company's growth strategy and operating strategy; and (iv) the declaration and payment of dividends. The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend," and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control, and actual results may differ materially from those projected in forward-looking statements resulting from various factors.

本新聞稿可能包含經修訂的1934年《證券交易法》(“交易法”)第21E條所指的前瞻性信息,包括所有非歷史事實陳述的關於公司、其董事或高級管理人員在以下方面的意圖、信念或當前預期的陳述:(i) 公司的融資計劃;(ii) 影響公司財務狀況或經營業績的趨勢;(iii) 公司的增長戰略和運營戰略;以及 (iv)申報和支付股息。“可能”、“將”、“將”、“期望”、“估計”、“預期”、“相信”、“打算” 等詞及其類似表達方式和變體旨在識別前瞻性陳述。投資者請注意,任何此類前瞻性陳述都不能保證未來的業績,並且涉及風險和不確定性,其中許多風險和不確定性超出了公司的控制能力,實際業績可能與前瞻性陳述中的預測存在重大差異 由於 各種因素。

SOURCE: Xcelerate, Inc.

來源: Xcelerate, Inc.


View source version on accesswire.com:
在 accesswire.com 上查看源代碼版本:

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論